Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06237127 · ClinicalTrials.gov registry record · NA

Effects of Goji vs. Fiber on Macular Degeneration

A NA study of Age-related Macular Degeneration, sponsored by University of California, Davis.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06237127 is a NA study of Age-related Macular Degeneration that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 60 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06237127, a NA study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.

Interventions

  • DIETARY_SUPPLEMENT Goji berry
  • DIETARY_SUPPLEMENT Fiber

Study Locations (1)

California

  • UC Davis Eye Center, Tschannen Eye Institute - Sacramento

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-04-29
Est. Completion 2027-06-30
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT06237127

The ClinicalTrials.gov registry entry for NCT06237127 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Goji berry is the first listed.

NCT06237127 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06237127 about?

NCT06237127 is a clinical study titled "Effects of Goji vs. Fiber on Macular Degeneration". The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on...

What is the current status of trial NCT06237127?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-04-29. Estimated completion is 2027-06-30.

What conditions does trial NCT06237127 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT06237127?

The interventions under investigation include: Goji berry (DIETARY_SUPPLEMENT), Fiber (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06237127?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06237127 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.